184 related articles for article (PubMed ID: 18034597)
1. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Cross SA; Lyseng-Williamson KA
Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG
Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353
[TBL] [Abstract][Full Text] [Related]
3. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
4. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
[TBL] [Abstract][Full Text] [Related]
5. Imatinib.
Lyseng-Williamson K; Jarvis B
Drugs; 2001; 61(12):1765-74; discussion 1775-6. PubMed ID: 11693465
[TBL] [Abstract][Full Text] [Related]
6. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Min CK; Kim HJ; Eom KS; Kim DW; Lee JW; Min WS; Kim CC
Blood; 2005 May; 105(9):3449-57. PubMed ID: 15657178
[TBL] [Abstract][Full Text] [Related]
7. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
Swords R
Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
[No Abstract] [Full Text] [Related]
8. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
9. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Pfeifer H; Scheuring U; Klein SA; Gökbuget N; Binckebanck A; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2002 Dec; 16(12):2358-65. PubMed ID: 12454740
[TBL] [Abstract][Full Text] [Related]
10. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
11. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Wassmann B
Drugs; 2007; 67(17):2656. PubMed ID: 18034598
[No Abstract] [Full Text] [Related]
12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
13. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Wassmann B; Pfeifer H; Scheuring UJ; Binckebanck A; Gökbuget N; Atta J; Brück P; Rieder H; Schoch C; Leimer L; Schwerdtfeger R; Ehninger G; Lipp T; Perz J; Stelljes M; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2004 Feb; 103(4):1495-8. PubMed ID: 14576058
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
[TBL] [Abstract][Full Text] [Related]
16. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
Schultz KR; Bowman WP; Aledo A; Slayton WB; Sather H; Devidas M; Wang C; Davies SM; Gaynon PS; Trigg M; Rutledge R; Burden L; Jorstad D; Carroll A; Heerema NA; Winick N; Borowitz MJ; Hunger SP; Carroll WL; Camitta B
J Clin Oncol; 2009 Nov; 27(31):5175-81. PubMed ID: 19805687
[TBL] [Abstract][Full Text] [Related]
17. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Brandwein J
Drugs; 2007; 67(17):2655. PubMed ID: 18034600
[No Abstract] [Full Text] [Related]
18. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
[TBL] [Abstract][Full Text] [Related]
19. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
Yoshimitsu M; Fujiwara H; Ozaki A; Hamada H; Matsushita K; Arima N; Tei C
Int J Hematol; 2008 Oct; 88(3):331-335. PubMed ID: 18696183
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]